Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143156 · ClinicalTrials.gov registry record · Phase 3
Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
NCT00143156 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 450 participants.
The verdict
NCT00143156, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of pregabalin administered twice a day compared to placebo in reducing pain in subjects with painful diabetic peripheral neuropathy.
Interventions
- DRUG pregabalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00143156
The ClinicalTrials.gov registry entry for NCT00143156 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pregabalin is the first listed.
NCT00143156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00143156 about?
NCT00143156 is a clinical study titled "Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy". To evaluate the efficacy and safety of pregabalin administered twice a day compared to placebo in reducing pain in subjects with painful diabetic peripheral neuropathy.
What is the current status of trial NCT00143156?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2005-03. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00143156?
The interventions under investigation include: pregabalin (DRUG).
Who is sponsoring clinical trial NCT00143156?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.